There Is A Quest For Clarity Surrounding BioAtla Inc (NASDAQ: BCAB) Volatility

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. The stock was recently discussed on Yahoo Finance as it revealed that BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Stocks Info

This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $2.47 and fluctuated between $2.6950 as its day high and $2.1950 as its day low. The current market capitalization of BioAtla Inc is $118.07M. A total of 1.5 million shares were traded on the day, compared to an average of 479.21K shares.

Insider Activity

Insider trades can also provide insight into a stock’s future direction. During the recent three months, BCAB has seen 1 BUY and 0 SELL insider trades, representing the acquisition of 4,000 and the disposition of 0 shares. Over the last 12 months, there were 9 BUYs and 39 SELLs from insiders. Insiders purchased 60,468 shares during that period but sold 40,280.

In the most recent transaction, MCBRINN SYLVIA bought 4,000 shares of BCAB for 2.33 per share on Dec 26. After the transaction, the Director now owns 15,125 company shares. In a previous transaction on Dec 20, SHORT JAY M PHD bought 50,000 shares at 2.14 per share. BCAB shares that Chief Executive Officer owns now total 1,439,283.

Among the insiders who bought shares, STEINMAN LAWRENCE acquired of 20,000 shares on Dec 19 at a per-share price of $2.05. This resulted in the Director holding 38,459 shares of BCAB after the transaction. In another insider transaction, Vasquez Christian bought 7,495 shares at $2.04 per share on Dec 19. Company shares held by the insider now total 115,659.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, BCAB has a high of $4.38 and a low of $1.24.

As of this writing, BCAB has an earnings estimate of -$0.79 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of -$0.71 per share and a lower estimate of -$1. The company reported an EPS of -$0.75 in the last quarter, which was -17.20% lower than expectations of -$0.64.

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. BCAB’s latest balance sheet shows that the firm has $244.98M in Cash & Short Term Investments as of fiscal 2021. There were $5.37M in debt and $19.81M in liabilities at the time. Its Book Value Per Share was $1.98, while its Total Shareholder’s Equity was $210.82M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BCAB is Buy with a score of 5.00.

Most Popular

Related Posts